Providers

Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.

A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.

Surveys of health care professionals, patients, and caregivers explored unmet needs in sickle cell disease (SCD), as well as the significant impact the disease has on everyday life.

Recommendations discuss appropriate use and diagnostic, prognostic, and therapeutic implications of cardiac genetic testing, including guidance on impact of exercise.

The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.

Levels of the hormone increase with disease severity, a new study has found.

According to the researchers of the study, managing patients with hidradenitis suppurativa holistically may help reduce the burden of their disease.

As part of the Biosimilars Initiative, British Columbia, Canada, implemented a mandatory switch to biosimilar insulin glargine for patients covered by the province’s drug plan.

Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.

The new trial was the first to investigate outcomes among a patient population living with HIV (PLWH) who were treated for anal precancerous growths, or high-grade squamous intraepithelial lesions.

Investigators said the benefits appeared relatively early in treatment for many patients and persisted throughout the study period.

Sex and age were associated with clinical characteristics of geriatric psoriasis, including type and location of disease, therapeutic considerations, and risk of comorbid nail involvement and psoriatic arthritis.

The Supreme Court has ruled that HHS' decision to lower reimbursement rates to hospitals so that those in the 340B program received reduced rates because they received discounted drugs was unlawful.

National Institutes of Health (NIH) researchers found a new form of macular dystrophy, which is a cause of central vision loss.

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

Oxidative stress, including DNA damage and malondialdehyde, was associated with dementia in patients with chronic obstructive pulmonary disease (COPD).

Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.

Amanda Ely is CEO of the Children’s HIV Association (CHIVA), an organization that provides support to children living with HIV in the United Kingdom and Ireland and their families.

The long-term study also found persistent residual risk of heart failure even after smoking cessation

Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center and University of Washington, discussed positive health-related quality of life (HRQOL) findings of the SEQUOIA trial investigating zanubrutinib vs bendamustine/rituximab in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Real-world studies evaluating the safety and efficacy of switching to adalimumab biosimilars from the originator product confirmed the safety and efficacy of the biosimilars ABP 501 and SB5.

A new model may be able to better identify which patients will respond to immunotherapy.

This new study, which the authors claim is the first to do so, investigated the relationship between COVID-19 vaccination status and survival outcomes among individuals with heart failure.

The study, based on 33 years of data, also explored auto-antibody production in the rare patient group.